Capstone Investment Advisors Has Decreased Allison Transmission Hldgs I (ALSN) Position; Profile of 3 Analysts Covering Roche Holding AG (RHHBY)

March 22, 2018 - By Linda Rogers

Capstone Investment Advisors Llc decreased Allison Transmission Hldgs I (ALSN) stake by 62.98% reported in 2017Q3 SEC filing. Capstone Investment Advisors Llc sold 38,983 shares as Allison Transmission Hldgs I (ALSN)’s stock rose 0.35%. The Capstone Investment Advisors Llc holds 22,917 shares with $860,000 value, down from 61,900 last quarter. Allison Transmission Hldgs I now has $5.40 billion valuation. The stock decreased 1.93% or $0.76 during the last trading session, reaching $38.52. About 434,498 shares traded. Allison Transmission Holdings, Inc. (NYSE:ALSN) has risen 38.35% since March 22, 2017 and is uptrending. It has outperformed by 21.65% the S&P500.

Among 5 analysts covering Roche Hldg (OTCMKTS:RHHBY), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Roche Hldg had 9 analyst reports since December 2, 2015 according to SRatingsIntel. As per Friday, January 22, the company rating was initiated by Piper Jaffray. Berenberg downgraded Roche Holding AG (OTCMKTS:RHHBY) on Tuesday, October 24 to “Hold” rating. Cowen & Co maintained the stock with “Buy” rating in Monday, August 14 report. Cowen & Co maintained it with “Buy” rating and $38.0 target in Thursday, October 19 report. The rating was upgraded by Citigroup on Wednesday, December 2 to “Buy”. The company was downgraded on Wednesday, October 18 by Citigroup. On Monday, July 10 the stock rating was maintained by Cowen & Co with “Buy”. Cowen & Co maintained the stock with “Buy” rating in Monday, September 18 report. See Roche Holding AG (OTCMKTS:RHHBY) latest ratings:

24/10/2017 Broker: Berenberg Rating: Hold Downgrade
19/10/2017 Broker: Cowen & Co Rating: Buy New Target: $38.0 Maintain
18/10/2017 Broker: Citigroup Rating: Hold Downgrade

Analysts await Allison Transmission Holdings, Inc. (NYSE:ALSN) to report earnings on April, 25. They expect $0.78 EPS, up 50.00% or $0.26 from last year’s $0.52 per share. ALSN’s profit will be $109.24M for 12.35 P/E if the $0.78 EPS becomes a reality. After $0.81 actual EPS reported by Allison Transmission Holdings, Inc. for the previous quarter, Wall Street now forecasts -3.70% negative EPS growth.

Since September 27, 2017, it had 0 buys, and 10 insider sales for $72.97 million activity. STAR JAMES A had sold 505,005 shares worth $22.55 million on Wednesday, January 10. Dick Michael sold 6,565 shares worth $288,872. Graziosi David S. sold $2.50 million worth of Allison Transmission Holdings, Inc. (NYSE:ALSN) on Tuesday, December 12. Scroggins Eric C. had sold 4,330 shares worth $190,533.

Capstone Investment Advisors Llc increased Kinder Morgan Inc Del (NYSE:KMI) stake by 28,770 shares to 52,846 valued at $1.01 million in 2017Q3. It also upped Vector Group Ltd stake by 1.66 million shares and now owns 16.50 million shares. Ishares Inc (EWY) was raised too.

Among 21 analysts covering Allison Transmission Holdings (NYSE:ALSN), 8 have Buy rating, 5 Sell and 8 Hold. Therefore 38% are positive. Allison Transmission Holdings had 76 analyst reports since July 30, 2015 according to SRatingsIntel. The firm earned “Overweight” rating on Friday, December 9 by JP Morgan. The rating was maintained by Stifel Nicolaus with “Hold” on Thursday, July 27. As per Wednesday, August 23, the company rating was maintained by Piper Jaffray. The firm has “Neutral” rating given on Thursday, October 12 by Longbow. Goldman Sachs downgraded the stock to “Neutral” rating in Monday, February 27 report. The rating was maintained by Deutsche Bank with “Hold” on Wednesday, August 2. JP Morgan maintained the stock with “Neutral” rating in Monday, October 30 report. Piper Jaffray maintained Allison Transmission Holdings, Inc. (NYSE:ALSN) on Friday, April 28 with “Sell” rating. The stock of Allison Transmission Holdings, Inc. (NYSE:ALSN) has “Hold” rating given on Thursday, August 17 by J.P. Morgan. The firm has “Sell” rating by Piper Jaffray given on Tuesday, October 31.

Investors sentiment increased to 1.1 in 2017 Q3. Its up 0.04, from 1.06 in 2017Q2. It is positive, as 39 investors sold ALSN shares while 84 reduced holdings. 50 funds opened positions while 80 raised stakes. 151.84 million shares or 0.94% less from 153.29 million shares in 2017Q2 were reported. Us Savings Bank De holds 25,782 shares or 0% of its portfolio. Wells Fargo And Mn invested 0.01% of its portfolio in Allison Transmission Holdings, Inc. (NYSE:ALSN). Hilltop Inc reported 0.12% of its portfolio in Allison Transmission Holdings, Inc. (NYSE:ALSN). Capstone Inv Advsrs Limited Liability Co owns 22,917 shares. Tiaa Cref Mngmt Ltd Liability Corp reported 1.54M shares or 0.04% of all its holdings. Pinebridge Investments Limited Partnership invested in 102,966 shares or 0.09% of the stock. Brandywine Glob Investment Mngmt Limited Liability Co has invested 0.01% in Allison Transmission Holdings, Inc. (NYSE:ALSN). Jennison Assocs Ltd Liability Co accumulated 1.79M shares or 0.07% of the stock. Ameriprise owns 31,412 shares or 0% of their US portfolio. Manufacturers Life Insur The reported 0% stake. Boothbay Fund Management Limited Liability invested 0.05% in Allison Transmission Holdings, Inc. (NYSE:ALSN). C M Bidwell & Assoc accumulated 0.04% or 715 shares. Nomura Incorporated, Japan-based fund reported 17,436 shares. Chicago Equity Prns Ltd Com accumulated 54,815 shares. 55,622 were accumulated by Pub Employees Retirement System Of Ohio.

The stock decreased 0.87% or $0.25 during the last trading session, reaching $28.49. About 1.41 million shares traded. Roche Holding AG (OTCMKTS:RHHBY) has 0.00% since March 22, 2017 and is . It has underperformed by 16.70% the S&P500.

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses worldwide. The company has market cap of $194.83 billion. The firm offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, drug metabolism disorder, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, human papillomavirus, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and west nile virus diseases. It has a 21.64 P/E ratio. It also provides diagnostic solutions for blood gas analysis; blood screening; cancer screening; cardiac markers; cardiovascular testing; cholesterol monitoring; coagulation monitoring, routing, and specialty testing; data management; diabetes monitoring and therapy; electrolytes analysis; emergency medicine; hemostasis; heterogeneous immunochemistry; homogenous immune assays; immunology; infectious diseases; intensive care testing; microarray; anti-platelet therapy monitoring; neonatal intensive care; nucleic acid purification; PCR clinical diagnostics and real-time PCR diagnostic systems; pharmacogenomics; physical fitness and platelet function testing; serum work area; urinalysis; and workflow solutions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: